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Abstract
Introduction: Smoking cessation programs are useful in helping smokers to quit, but smoking is a very difficult
addiction to break and the need for novel and effective approaches to smoking cessation interventions is
unquestionable. The E-cigarette is a battery-powered electronic nicotine delivery device that may help smokers to
remain abstinent during their quit attempt. We report for the first time objective measures of smoking cessation in
smokers who experimented with the E-cigarette.
Case presentation: Three Caucasian smokers (two men aged 47 and 65 years and one woman aged 38 years)
with a documented history of recurring relapses were able to quit and to remain abstinent for at least six months
after taking up an E-cigarette.
Conclusions: This is the first time that objective measures of smoking cessation are reported for smokers who quit
successfully after using an E-cigarette. This was accomplished in smokers who repeatedly failed in previous
attempts with professional smoking cessation assistance using the usual nicotine dependence treatments and
smoking cessation counselling.
Introduction
Cigarette smoke harms nearly every system of the
human body, thus causing a broad range of diseases,
many of which are fatal [1,2]. The risk of serious disease
diminishes rapidly after quitting and life-long abstinence
is known to reduce the risk of lung cancer, heart dis-
ease, strokes, chronic lung disease and other cancers
[3,4]. Although evidence-based recommendations indi-
cate that smoking cessation programs are useful in help-
ing smokers to quit [5], smoking is a very difficult
addiction to break. It has been shown that approxi-
mately 80% of smokers who attempt to quit on their
own relapse within the first month of abstinence and
only about 3% to 5% remain abstinent at six months [6].
Although there is little doubt that currently-marketed
smoking cessation products increase the chance of com-
mitted smokers stopping smoking, they reportedly lack
high levels of efficacy - particularly in the real life set-
ting [7]. Although this is known to reflect the chronic
relapsing nature of tobacco dependence, the need for
novel and effective approaches to smoking cessation
interventions is unquestionable.
The E-cigarette is a battery-powered electronic nico-
tine delivery device (ENDD), often resembling a cigar-
ette. It is designed to deliver nicotine to the respiratory
system, where neither tobacco nor combustion are
necessary for its operation [8] (Figure 1). Consequently,
it is likely that this product may be considered as a
lower risk substitute for factory-made cigarettes. In
addition, people report buying them to help quit smok-
ing, to reduce cigarette consumption, and to relieve
tobacco withdrawal symptoms due to workplace smok-
ing restrictions [9]. Besides delivering nicotine to the
lung, E-cigarettes may also provide a coping mechanism
for conditioned smoking cues by replacing some of the
rituals associated with smoking gestures (for example
the hand-to-mouth action of smoking). For this reason,
E-cigarettes may help smokers to remain abstinent dur-
ing their quit attempt. To date there has been no formal
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in smoking cessation studies.
To the best of our knowledge, we report for the first
time objective measures of smoking cessation in three
heavy smokers who experimented with the E-cigarette.
Case presentations
In this case series we describe three heavy smokers with
an established history of relapses who have been repeti-
tively managed for nicotine dependence at our university
clinic for smoking cessation (Centro per la Prevenzione
eC u r ad e lT a b a g i s m o-C P C T ;U n i v e r s i t àd iC a t a n i a ;
Italy). Our patients (two men aged 47 and 65 years and
one woman aged 38 years), were of Caucasian ethnicity.
At CPCT, smoking cessation programs are based on an
adaptation of the Clinical Practice Guideline on Smok-
ing Cessation of the U.S. Department of Health and
Human Services [5] and have been described previously
in detail [10]. The staff at CPCT includes a dedicated
team of clinical psychologists, physicians, and nurses
with at least three years of experience.
Patient 1
A 47-year-old Caucasian male lawyer with a diagnosis of
severe nicotine dependence attended our smoking cessa-
tion clinic four years ago. He smoked 32 cigarettes per
day (45 pack/years) with a significant level of nicotine
dependence (Fagerstrom Test of Nicotine Dependence -
FTND = 8). His concentration of exhaled breath carbon
monoxide (eCO) reading at baseline was 31 ppm. No
history of alcohol abuse, major depression or other psy-
chiatric conditions was reported. He was subjected to
intensive treatment for nicotine dependence four years
ago and subsequently after seven months. He partici-
pated in other intensive treatments for nicotine depen-
dence three years ago and two years ago. On each
occasion, he was prescribed a combination of nicotine
patches and bupropion and was offered smoking cessa-
tion counselling throughout the program. His last
relapse occurred one month after treatment’.D u r i n ga
routine telephone follow-up two years ago, he reported
having quit smoking on his own after taking up an E-
cigarette. He was then invited to visit our clinic to allow
us to collect more informations and conduct further
investigations. He told us that he started experimenting
with an E-cigarette (loaded with a high nicotine concen-
tration: 7.2 mg nicotine per cartridge) two years ago. A
few weeks later, he was able to discontinue tobacco
smoking completely. He kept using his E-cigarette for
another few months before stopping use of the E-cigar-
ette as well. Abstinence from tobacco smoking was then
objectively assessed by measuring the concentration of
exhaled breath carbon monoxide concentration (eCO);
the measured eCO value was within the normal range
Figure 1 The E-cigarette is a battery-powered electronic nicotine delivery device (ENDD) designed for the purpose of providing
inhaled doses of nicotine by way of a vaporized solution to the respiratory system. This device provides a flavor and physical sensation
similar to that of inhaled tobacco smoke, while no smoke or combustion is actually involved in its operation. It is composed of the following key
components: (1) the inhaler - also known as ‘cartridge’ (a disposable plastic mouthpiece - resembling a tobacco cigarette’s filter - which contains
an absorbent material that is saturated with a liquid solution containing nicotine); (2) the atomizing device (the heating element that vaporizes
the liquid in the mouthpiece and generates the mist with each puff); (3) the battery component (the body of the device - resembling a tobacco
cigarette - which houses a lithium-ion re-chargeable battery to power the atomizer). The body of the device also houses an electronic airflow
sensor to automatically activate the heating element upon inhalation and to light up a LED (Light Emitting Diode) indicator to signal activation
of the device with each puff.
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smoking for approximately six months with no reported
lapse or relapse during this period of time. The E-cigar-
ette was well tolerated with no reported adverse effects.
Patient 2
A 38-year-old Caucasian female social worker with a
diagnosis of severe nicotine dependence attended our
smoking cessation clinic four years ago. She smoked 28
cigarettes per day (28 pack/years) with a significant level
of nicotine dependence (FTND = 8). Her eCO reading
at baseline was 29 ppm. Some mild depression assessed
by the Self-rating Depression Scale (SDS) was also docu-
mented in her case notes. She was treated for nicotine
dependence at our clinic four years ago and again two
years ago. On each occasion, she was prescribed nico-
tine patches and bupropion. She was offered smoking
cessation counselling throughout the program. Her last
relapse occurred two years ago.
D u r i n gar o u t i n et e l e p h o n ef o l l o w - u po n ey e a ra g o ,
she reported having quit smoking on her own after tak-
ing up an E-cigarette. She was then invited for a follow-
up visit at our clinic, during which abstinence was
reviewed objectively by measuring the concentration of
eCO. She told us that she had started experimenting
with an E-cigarette (loaded with high nicotine concen-
tration: 7.2 mg nicotine per cartridge) two years ago.
Three months later, she was able to discontinue tobacco
smoking completely. She kept using the E-cigarette with
a high nicotine concentration for another month before
switching to mentholated cartridges, which she now
uses frequently during social events.
Abstinence from tobacco smoking was confirmed
objectively by very low levels of eCO (eCO = 2 ppm).
She has been abstinent from tobacco smoking for
approximately seven months with no reported lapse or
relapse during this period of time. Overall, the E-cigar-
ette was well tolerated with occasional dry cough being
reported.
Patient 3
A 65-year-old Caucasian male pharmacist with a
known diagnosis of chronic obstructive pulmonary dis-
ease (COPD) was seen for a routine follow up in our
chest clinic two years ago. He had been a heavy smo-
ker for nearly 50 years (89 pack/years) and had a past
history of alcohol abuse. He was treated for nicotine
dependence twice by the local services for addiction on
two occasions seven years ago and four years ago. On
both occasions he was prescribed nicotine patches and
attended group counselling sessions. Four years ago, he
came to our smoking cessation clinic. He smoked 30
to 40 cigarettes per day with a significant level of nico-
tine dependence (FTND = 10). His eCO baseline
reading was 34.9 ppm. He was started on varenicline
(a partial agonist of the a4b2 nicotinic acetylcholine
receptor approved specifically for smoking cessation
therapy) in association with smoking cessation coun-
selling, but he was lost to follow-up by one month
after his quit date.
When he came for his routine follow-up appointment
at the chest clinic two years ago, he announced that he
had quit tobacco smoking on his own after taking up an
E-cigarette loaded with nicotine cartridges. Two months
after taking up an E-cigarette loaded with nicotine car-
tridges, he was able to discontinue tobacco smoking
completely. He continued using his E-cigarette on a reg-
ular basis. Predictably, this patient noted a significant
improvement in quality of life, manifested by increased
energy levels and exercise tolerance. Moreover, he has
reported no significant exacerbations of his symptoms
during the past two years.
Abstinence from tobacco smoking was confirmed
objectively by measuring the concentration of exhaled
breath carbon monoxide concentration (eCO); the mea-
sured eCO value being within the normal range (eCO =
5 ppm). The E-cigarette was well tolerated with no
reported adverse events.
Discussion
This is the first time that objective measures of smoking
cessation are reported in smokers with a documented
history of recurring relapses, who quit smoking after
taking up an E-cigarette with the intention of quitting
tobacco smoking. This was accomplished by heavy smo-
kers who repeatedly failed in previous attempts with
professional smoking cessation assistance based on the
usual nicotine dependence treatments and smoking ces-
sation counselling. Some studies have found that multi-
ple failed attempts have a negative effect on a smoker’s
confidence in being able to quit smoking cigarettes [11].
The COPD patient was a particularly difficult case
with an FTND of 10 (maximum score) and a documen-
ted history of recurring relapses. The available evidence
in the medical literature indicates that, in contrast with
smokers in the general population, COPD patients who
smoke typically respond poorly to smoking cessation
efforts; they have a greater degree of physical nicotine
dependence [12] and appear to be less motivated to quit
smoking [13].
We cannot discount that the success observed in our
patients may be simply due to the repeated number of
quit attempts and not necessarily to E-cigarette use.
However, we later contacted these patients and asked if
they took up the E-cigarette with the intention to quit
a n di ft h e yb e l i e v e dt h a tt h e yw o u l dn o th a v eq u i ti fi t
weren’t for the E-cigarettes. Answers to both questions
were positive for all three patients. Thus, these patients
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without the help of E-cigarettes.
The remarkable success stories of these three smokers
require consideration. The widely acknowledged benefi-
cial role of pharmacotherapy in smoking cessation is
likely to be due to its ability to address the physical
component of tobacco dependence. However, taking
pills or patches for nicotine addiction is unlikely to
resolve the psychological components associated with
tobacco dependence. As a matter of fact smoking is
much more than the addicting effect of nicotine; the
smoking habit also includes the rituals that each smoker
associates with his or her habit [14]. Smoking cessation
products cannot replace the rituals associated with the
act of smoking.
Counselling for smoking cessation is intended to help
smokers in coping with this important aspect of their
life by implementing personalized replacement rituals,
but even counselling for smoking cessation lacks high
levels of efficacy. Therefore, it is likely that the smokers
described in our case series coped successfully with the
psychological components associated with their tobacco
dependence by using a device resembling a cigarette,
which - although being mainly designed for the purpose
of nicotine delivery to the respiratory system - has the
additional advantage of being a valid substitute for the
tactile sensations of the cigarette and other sensations
associated with smoking gestures.
An important aspect that needs to be highlighted in
relation to the findings of the present case series is the
putative risk of E-cigarettes. In June 2009, the US Food
and Drug Administration (FDA) announced in a press
conference that ‘a laboratory analysis of electronic cigar-
ette samples has found that they contain carcinogens
and toxic chemicals such as diethylene glycol (DEG), an
ingredient used in antifreeze’ [15]. The actual lab report
revealed that the ‘carcinogens’ referred to in the FDA’s
press conference were tobacco specific nitrosamines
(TSNAs), but failed to specify the quantity detected.
The FDA’s report did state that the quantity of DEG
detected in the liquid in one of the 18 samples was 1%
(0.01 ml), but did not point out that this is a non-toxic
quantity. The FDA did not report finding DEG, or any
other harmful chemical, in the vapor [16]. A number of
reports available over the Internet have subsequently
characterized, quite extensively, the components con-
tained in E-cigarette liquid and vapor using gas chroma-
tography mass spectrometry (GC-MS). They
demonstrate that the primary components of E-cigarette
cartridges are propylene glycol (PG), glycerin, and nico-
tine [17]. Laugesen tested E-cigarette mist for more than
50 priority-listed cigarette smoke toxicants and found
none [18]. This report only revealed traces (8.2 ng/g) of
TSNAs in the ‘high’ nicotine cartridge of an E-cigarette.
It must be noted that this amount is equal to the
quantity reported to be present in a nicotine medicinal
patch.
Recently, Cahn and Siegel have reviewed the results of
16 laboratory analyses of E-cigarette liquid, including
the FDA’s ‘Final Report’. TSNAs were reported in two
studies, but at trace levels, which are similar to those
found in a nicotine patch, and, most importantly, about
500-fold to 1400-fold lower than TSNA levels measured
in regular cigarettes. The presence of DEG was reported
in the FDA’s report in one of the 18 cartridges, yet none
of the other 15 studies found any DEG. The authors sta-
ted, ‘Other than TSNAs and DEG, few, if any, chemicals
at levels detected in E-cigs raise serious health concerns.
Although the current data are insufficient to conclude
that E-cigarettes are safe in absolute terms and that
further studies are needed to comprehensively assess
their safety, these products appear to be much safer
than tobacco cigarettes and comparable in toxicity to
conventional nicotine replacement products’ [19].
In a recent prospective proof-of-concept study, we
monitored possible modifications in the smoking habits
of 40 smokers not willing to quit who were experiment-
ing with a 7.4 mg nicotine/cartridge E-cigarette [20].
Combined sustained smoking reduction and smoking
abstinence was shown in 55% of the participants, with
an overall 88% fall in the number of cigarettes smoked
per day. Mouth and throat irritation, and dry cough
were common, but diminished substantially by the end
of the study. Retailers all over the world have already
sold hundreds of thousands of E-cigarettes, yet there is
no evidence that these products have endangered
anyone.
L a s t l y ,t h e r em a yb es o m ec o n c e r nt h a tn o n - s m o k e r s
might take up use of an E-cigarette, become addicted to
nicotine, and eventually start to smoke tobacco cigar-
ettes. The fear of this ‘gateway effect’ has been men-
tioned in connection with the European Union ban on
the sale of snus, a type of smokeless tobacco that is
neither chewed nor smoked. The available evidence
would indicate that snus provides a gateway out of
smoking rather than into it. Snus is a type of finely
ground moist snuff that delivers significant levels of
nicotine. Snus does not produce any of the toxic com-
bustion products and it is manufactured in a way that
produces low levels of tobacco-specific nitrosamines, the
main carcinogens responsible for oral cancers in users
of other smokeless tobacco products [21].
Sweden now has one of the lowest smoking preva-
lence rates in the world [22]. Ranstrom and Foulds
found the odds of initiating daily smoking were signifi-
cantly lower for men who had started using snus than
for those who had not (odds ratio (OR) = 0.28, 95%
confidence interval (CI) 0.22 to 0.36) [23]. Another
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cantly higher for daily snus users in six of seven data
sets collected during 2003 to 2008 in Norway [24]. In
the United States of America (USA) 73% of the most
recent quit attempts using smokeless tobacco resulted in
smokers achieving smoking abstinence [25].
In a survey that included 3037 ever-users of E-cigar-
ettes, only one of the 2850 respondents who used nico-
tine-containing E-cigarettes was a never-smoker [26].
The authors of the study did not report the reason.
Given the fact that 70% of the ever-users succeeded in
quitting smoking, the E-cigarette would also appear to
be a gateway away from smoking. In previous quit
attempts, 70.5% had tried nicotine therapy, 29.1% used
bupropion, and 19.4% used varenicline. Users of both
snus and E-cigarettes might be less likely to later switch
to smoking if governments and health organizations
made it clear that smoking carries enormously greater
health risks than nicotine that comes from non-smoked
sources.
Obviously, these products need to be adequately regu-
lated, but thus far, there have been heterogeneous regu-
latory responses. Some countries have completely
banned the sale and marketing of E-cigarettes whereas
others allow marketing within their regulatory frame-
works. Internet marketing of E-cigarettes and the inade-
quacy and misapplication of import product codes,
however, impede systematic regulation [27]. More
research on E-cigarettes must be conducted in order to
ensure that the decisions of regulators, healthcare provi-
ders and consumers are evidence-based.
Conclusions
The most important message from this case series is
that these smokers, with a documented history of recur-
ring relapses, were able to quit smoking and to remain
abstinent for at least six months after taking up an elec-
tronic cigarette. Although the present findings cannot
be generalized, high quit rates would be desirable in a
population that generally responds poorly to smoking
cessation efforts. Larger controlled studies are needed to
confirm this interesting finding, particularly for those
smokers for whom the handling and manipulation of
their cigarettes play an important part of the ritual of
smoking.
Consent
Written informed consent was obtained from the
patients for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
Acknowledgements
Riccardo Polosa is full Professor of Internal Medicine and he is supported by
the University of Catania, Italy.
Author details
1Centro per la Prevenzione e Cura del Tabagismo (CPCT), Dipartimento di
Biomedicina Clinica e Molecolare, Azienda Ospedaliero-Universitaria “V.
Emanuele-Policlinico”, Università di Catania, Catania, Italy.
2Institute of
Internal Medicine, S. Marta Hospital, Azienda Ospedaliero-Universitaria “V.
Emanuele-Policlinico”, Università di Catania, Catania, Italy.
3Unità Operativa
Geriatria, Dipartimento di Chirurgia Sessione Geratria, Ospedale Cannizzaro,
Università di Catania, Catania, Italy.
Authors’ contributions
RP, PC, CR, CL and DC were responsible for the study conception, data
retrieval and draft of the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 March 2011 Accepted: 20 December 2011
Published: 20 December 2011
References
1. Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking:
50 years’ observations on male British doctors. BMJ 2004, 328:1519-1528.
2. Boyle P, Gray N, Henningfield J, Seffrin J, Zatonski W: Tobacco and Public
Health: Science and Policy Oxford: Oxford University Press; 2004.
3. US Department of Health and Human Services: The health benefits of
smoking cessation (DHHS Publication No. (CDC) 90-8516). USA, US
Department of Health and Human Services, Public Health Service, Centers
for Disease Control, Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health; 1990.
4. Lightwood JM, Glantz SA: Short-term economic and health benefits of
smoking cessation. Circulation 1997, 96:1089-1096.
5. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, et al: Treating
tobacco use and dependence: 2008 update. US Dept of Health and
Human Services, Public Health Service; 2008.
6. Hughes JR, Keely J, Naud S: Shape of the relapse curve and long-term
abstinence among untreated smokers. Addiction 2004, 99:29-38.
7. Casella G, Caponnetto P, Polosa R: Therapeutic advances in the treatment
of nicotine addiction: present and future. TACD 2010, 1:95-106.
8. Hon L: A non-smokable electronic spray cigarette (CA 2518174) (Patent
notice). Canadian Patent Office Record 2005, 133:129.
9. Zezima K: Cigarettes without smoke or regulation. New York Times 2009
[http://www.nytimes.com/2009/06/02/us/02cigarette.html].
10. Piccillo G, Caponnetto P, Barton S, Russo C, Origlio A, Bonaccorsi A, Di
Maria A, Oliveri C, Polosa R: Changes in airway hyperresponsiveness
following smoking cessation: comparisons between Mch and AMP. Respir
Med 2008, 102:256-265.
11. Owen N, Brown SL: Smokers unlikely to quit. J Behav Med 1991,
14:627-636.
12. Jimenez-Ruiz CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C,
Sobradillo V: Smoking characteristics: differences inattitudes and
dependence between healthy smokers and smokers with COPD. Chest
2001, 119:1365-1370.
13. Walters N, Coleman T: Comparison of the smoking behaviour and
attitudes of smokers who attribute respiratory symptoms to smoking
with those who do not. Br J Gen Pract 2002, 52:132-134.
14. Laurier E, McKie L, Goodwin N: Daily and life course contexts of smoking.
Sociol Health Illn 2000, 22:289-309.
15. US Food and Drug Administration: FDA News Release: FDA and public
health experts warn about electronic cigarettes. 2009 [http://www.fda.
gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm173222.htm],
(accessed July 2011).
16. US Food and Drug Administration: Final report on FDA analyses. 2009
[http://www.fda.gov/downloads/Drugs/ScienceResearch/UCM173250.pdf],
(accessed June 2011).
Caponnetto et al. Journal of Medical Case Reports 2011, 5:585
http://www.jmedicalcasereports.com/content/5/1/585
Page 5 of 617. Alliance Technologies: Characterization of liquid “smoke juice” for
electronic cigarettes. 2009 [http://cdn.johnsoncreeksmokejuice.com/
downloads/JCE_GCMS_Report.pdf], (accessed June 2011).
18. Laugesen M: Ruyan e-cigarette bench-top tests. Poster. Society for
Research on Nicotine and Tobacco Conference, Dublin; 2009 [http://www.
healthnz.co.nz/DublinEcigBenchtopHandout.pdf], (accessed May 2011).
19. Cahn Z, Siegel M: Electronic cigarettes as a harm reduction strategy for
tobacco control: A step forward or a repeat of past mistakes? J Public
Health Policy 2011, 32:16-31.
20. Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C: Effect
of an electronic nicotine delivery device (e-cigarette) on smoking
cessation and reduction: a prospective pilot study. BMC Public Health
2011, 11:786.
21. Osterdahl B-G, Jansson C, Paccou A: Decreased levels of tobacco specific
N-nitrosamines in moist snuff on the Swedish market. J Agric Food Chem
2004, 52:5085-5088.
22. Fagerström KO, Schildt EB: Should the European Union lift the ban on
snus? Evidence from the Swedish experience. Addiction 2003,
98:1191-1195.
23. Ramström LM, Foulds J: Role of snus in initiation and cessation of
tobacco smoking in Sweden. Tob Control 2006, 15:210-214.
24. Lund KE, Scheffels J, McNeill A: The association between use of snus and
quit rates for smoking: results from seven Norwegian cross-sectional
studies. Addiction 2011, 106:162-167.
25. Kozlowski LT, O’Connor RJ, Edwards BQ, Flaherty BP: Most smokeless
tobacco use is not a causal gateway to cigarettes: using order of
product use to evaluate causation in a national US sample. Addiction
2004, 99:260-262.
26. Etter JF, Bullen C: Electronic cigarette: users profile, utilization,
satisfaction and perceived efficacy. Addiction 2011, 106:2017-2028.
27. World Health Organization (WHO) Study Group on Tobacco Product
Regulation: Report on the scientific basis of tobacco product regulation:
third report of a WHO study group. WHO technical report series 2009, no.
955 [http://whqlibdoc.who.int/publications/2009/9789241209557_eng.pdf],
(accessed June 2011).
doi:10.1186/1752-1947-5-585
Cite this article as: Caponnetto et al.: Successful smoking cessation with
electronic cigarettes in smokers with a documented history of recurring
relapses: a case series. Journal of Medical Case Reports 2011 5:585.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Caponnetto et al. Journal of Medical Case Reports 2011, 5:585
http://www.jmedicalcasereports.com/content/5/1/585
Page 6 of 6